Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief Report

Serological survey following SARS-COV-2 outbreaks at long-term care facilities in metro Vancouver, British Columbia: Implications for outbreak management and infection control policies

Rohit Vijh MD a,*, Cher Ghafari MPH b, Althea Hayden MD, MPH a,b, Michael Schwandt MD, MPH a,b, Inna Sekirov MD, PhD c,d, Muhammad Morshed PhD c,d, Paul Levett PhD, DSc c,d, Mel Krajden MD c,d, Suni Boraston MD b, Patricia Daly MD, MSc a,b, Mark Lysyshyn MD, MPH a,b, John Harding MB, BCH, BOA, MPH a,b, Meghan McLennan BSc, MLT e, Navdeep Chahil BSc, RT c, Annie Mak BSc, RT c, Geoff McKee MD, MPH a,b

a School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
b Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada
c British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, British Columbia, Canada
d Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
e Provincial Laboratory Medicine Services, Provincial Health Services Authority, Vancouver, British Columbia, Canada

Keywords:
COVID-19
Public health
Case identification
Case exclusion
Clinical case definition
Serology

ABSTRACT

A cross-sectional serological survey was carried out in two long-term care facilities that experienced COVID-19 outbreaks in order to evaluate current clinical COVID-19 case definitions. Among individuals with a negative or no previous COVID-19 diagnostic test, myalgias, headache, and loss of appetite were associated with serological reactivity. The US CDC probable case definition was also associated with seropositivity. Public health and infection control practitioners should consider these findings for case exclusion in outbreak settings.

Communicable disease case definitions can be utilized in public health for a variety of purposes (e.g., surveillance). In the context where diagnostic tests are not rapidly available or have limited sensitivity, symptom-based case definitions are essential. In LTC outbreaks, uncontrolled introduction of infections not identified through testing may perpetuate transmission despite outbreak control measures. Currently, various national probable/epidemiologically-linked (clinical) case definitions largely focus on respiratory symptoms (i.e., cough and shortness of breath), with varying inclusion of systemic/generalized symptoms (i.e., fever, chills, loss of appetite) (Appendix A). Given LTC residents often present with nonspecific generalized symptoms for other respiratory pathogens; potential cases of COVID-19 are likely missed and potentially contribute to propagation within LTC facilities.

Our analysis aims to provide a descriptive overview of a serological survey of LTC residents and staff members following outbreaks at 2 facilities and evaluate clinical case definitions of COVID-19 used in LTC outbreaks against serological results.
METHODS

A cross-sectional serological survey of LTC residents and staff members was administered from May 4th to 14th, 2020 at 2 adult LTC facilities located in the Metro Vancouver area, British Columbia. These LTC facilities experienced large outbreaks, in which 107 residents and 59 staff had become COVID-19 cases at the time of serological sample collection. The onset of the outbreaks at the 2 facilities were March 5th (Facility A) and March 17th (Facility B), 2020. Individuals (or their substitute decision maker) working (staff) or living (resident) in the LTC facility during the outbreaks were included after providing informed verbal consent for venous blood specimen collection.

Venous specimens were tested using an orthogonal approach with 5 different commercially-available SARS-CoV-2 antibody assays with varying target immunoglobulin and epitopes. Symptom onset dates were captured using both clinical information and diagnostic test data. Resident symptoms were documented through a combination of resident report/staff observation and utilization of a standardized symptom checklist. Symptom onset dates were captured as immunocompromised using provincial criteria (Appendix F). Data on residents was gathered by abstracting data from a standardized case report form (Appendix C), medical charts of LTC residents, and phone interviews. Clinical information (symptomatic/asymptomatic history, symptom clusters (Appendix A), and laboratory results (NAAT) for SARS-CoV-2 per-panel best practice guidelines. Specimens were tested utilizing an orthogonal approach with 5 different commercially-available SARS-CoV-2 antibody assays with varying target immunoglobulin and epitopes. Each individual was assigned by a medical microbiologist into “reactive”, “nonreactive” or “equivocal” category based on degree of agreement/disagreement of aggregate antibody results from all tests.

All nucleic acid amplification tests (NAAT) for SARS-CoV-2 performed on nasopharyngeal swab samples testing were carried out in fully accredited clinical laboratories for clinical purposes, following routine best practice guidelines. Specimens were tested utilizing either a fully validated laboratory developed test targeting the E-gene and RdRP gene regions of SARS-CoV-2 (BC Center for Disease Control Public Health Laboratory), a fully validated laboratory developed test targeting the E-gene region of SARS-CoV-2, or a fully validated commercially developed cobas SARS-CoV-22 test targeting the orf-1a/b and E-gene regions of SARS-CoV-2 (St Paul's Hospital). All nucleic acid amplification tests (NAAT) for SARS-CoV-2 performed on nasopharyngeal swab samples testing were carried out in fully accredited clinical laboratories for clinical purposes, following routine best practice guidelines. Specimens were tested utilizing either a fully validated laboratory developed test targeting the E-gene and RdRP gene regions of SARS-CoV-2 (BC Center for Disease Control Public Health Laboratory), a fully validated laboratory developed test targeting the E-gene region of SARS-CoV-2, or a fully validated commercially developed cobas SARS-CoV-22 test targeting the orf-1a/b and E-gene regions of SARS-CoV-2 (St Paul's Hospital). Clinical information (symptomatic/asymptomatic history, symptoms recorded, medical comorbidities, medications) for each individual was gathered by abstracting data from a standardized case report form (Appendix C), medical charts of LTC residents, and phone interviews. Resident symptoms were documented through a combination of resident report/staff observation and utilization of a standardized symptom checklist (Appendix D). Symptom onset dates were captured using both clinical information and diagnostic test data (Appendix E). Participants were classified as immunocompromised or immunocompetent using provincial criteria (Appendix F). Data on clinical information and diagnostic test results were abstracted from May 22nd to June 5th 2020.

RESULTS

Serological testing was offered to all residents and staff in both facilities, with 44% (303/691) consenting to participate (48% staff, 39% residents). A total of 303 LTC residents (n = 127) and staff (n = 176) were included in the study. After excluding 12 individuals with equivocal serological results, 39% (n = 113) were reactive and 61% (n = 178) were nonreactive. Table 1 provides a descriptive epidemiological summary of study participants. The median time between symptom onset and serological collection was 50 days (IQR = 15) for the entire cohort, 52 days (IQR = 9.5) for NAAT positive cases, and 48 days (IQR = 23.5) for no or negative NAAT cases.

Among the entire study cohort, loss of smell/taste (aOR = 45.98, 95% confidence interval [CI]: 5.12-412.72), shortness of breath (aOR = 21.22, 95%CI: 5.91-76.22), headache (aOR = 13.00, 95%CI:5.47-30.86), loss of appetite (aOR = 10.94, 95%CI:1.27-94.53), fatigue (aOR = 10.90, 95% CI: 4.48-26.48), and myalgia (aOR = 10.80, 95% CI: 4.55-25.60) were most prominently associated with increased odds of reactive serology (Fig 1A). All symptom cluster case definitions were significantly associated with seropositivity (Fig 1C). Participant immune status was not associated with seropositivity (aOR = 0.29, 95%CI: 0.05-1.66), even among residents only (aOR = 0.83, 95%CI: 0.08-9.07). At last, the absence of recorded symptoms was associated with decreased odds of being seropositive (aOR = 0.08, 95%CI: 0.04-0.15).

Among, individuals with a negative or no previous NAAT, only myalgias (aOR = 7.51, 95%CI:2.00-28.25), headache (aOR = 14.27, 95%CI:3.78-53.90), loss of appetite (aOR = 33.23, 95%CI:3.19-345.90),
and ≥3 negative NAAT (aOR = 29.04, 95%CI:5.60-150.57) were significantly associated with increased odds of reactive serology (Fig 1B).

Various national clinical case definitions were evaluated (Fig 1D) for individuals with no or negative prior NAAT in the context of a high-risk outbreak setting. No significant association with serological reactivity was observed using the Canadian (aOR = 1.64, 95% CI: 0.58-4.62), European (aOR = 1.59, 95% CI: 0.57-4.49), or World Health Organizations’ (WHO) (aOR = 3.55, 95% CI: 0.48-26.46) definitions; however, a significant association was observed for the US CDC case definition (aOR = 3.56, 95% CI: 1.21-10.45). Other significant case definitions included having at least one systemic symptom (aOR = 4.54, 95% CI: 1.74-11.82) and fever with one additional systemic symptom (aOR = 9.89, 95% CI: 2.28-42.84).

DISCUSSION

Findings of this study are consistent with the results published by Menni et al, which also demonstrated a strong association between COVID-19 diagnosis and systemic symptoms; however, our findings provide additional insight to inform outbreak management practices and policies in LTC facilities. Our study also contributes to the growing evidence for mild/atypical presentations of COVID-19 particularly among the elderly, such as dizziness, nausea, and vomiting are not reported in 1B due to extremely broad confidence intervals. (C and D) Depict aORs (on a log10 scale) for seropositivity of symptom clusters (Appendix A) among the entire population (1C) or among individuals with a negative or no NAAT test prior to serological testing (1D). Anosmia, dizziness, nausea, and vomiting are not reported in 1B due to extremely broad confidence intervals. (C and D) Depict aORs (on a log10 scale) for seropositivity of symptom clusters (Appendix A) among the entire population (1C) or among individuals with a negative or no NAAT test prior to serological testing (1D). Anosmia, loss of smell/taste; SOB, shortness of breath/difficulty breathing; PHAC, Public Health Agency of Canada; US CDC, United States Centre for Disease Control; European CDC, European Centre for Disease Prevention and Control; WHO, World Health Organization.

and ≥3 negative NAAT (aOR = 29.04, 95%CI:5.60-150.57) were significantly associated with increased odds of reactive serology (Fig 1B).

Various national clinical case definitions were evaluated (Fig 1D) for individuals with no or negative prior NAAT in the context of a high-risk outbreak setting. No significant association with serological reactivity was observed using the Canadian (aOR = 1.64, 95% CI: 0.58-4.62), European (aOR = 1.59, 95% CI: 0.57-4.49), or World Health Organizations’ (WHO) (aOR = 3.55, 95% CI: 0.48-26.46) definitions; however, a significant association was observed for the US CDC case definition (aOR = 3.56, 95% CI: 1.21-10.45). Other significant case definitions included having at least one systemic symptom (aOR = 4.54, 95% CI: 1.74-11.82) and fever with one additional systemic symptom (aOR = 9.89, 95% CI: 2.28-42.84).

DISCUSSION

Findings of this study are consistent with the results published by Menni et al, which also demonstrated a strong association between COVID-19 diagnosis and systemic symptoms; however, our findings provide additional insight to inform outbreak management practices and policies in LTC facilities. Our study also contributes to the growing evidence for mild/atypical presentations of COVID-19 particularly among the elderly, such as dizziness, nausea, and vomiting are not reported in 1B due to extremely broad confidence intervals. (C and D) Depict aORs (on a log10 scale) for seropositivity of symptom clusters (Appendix A) among the entire population (1C) or among individuals with a negative or no NAAT test prior to serological testing (1D). Anosmia, dizziness, nausea, and vomiting are not reported in 1B due to extremely broad confidence intervals. (C and D) Depict aORs (on a log10 scale) for seropositivity of symptom clusters (Appendix A) among the entire population (1C) or among individuals with a negative or no NAAT test prior to serological testing (1D). Anosmia, loss of smell/taste; SOB, shortness of breath/difficulty breathing; PHAC, Public Health Agency of Canada; US CDC, United States Centre for Disease Control; European CDC, European Centre for Disease Prevention and Control; WHO, World Health Organization.

and ≥3 negative NAAT (aOR = 29.04, 95%CI:5.60-150.57) were significantly associated with increased odds of reactive serology (Fig 1B).

Various national clinical case definitions were evaluated (Fig 1D) for individuals with no or negative prior NAAT in the context of a high-risk outbreak setting. No significant association with serological reactivity was observed using the Canadian (aOR = 1.64, 95% CI: 0.58-4.62), European (aOR = 1.59, 95% CI: 0.57-4.49), or World Health Organizations’ (WHO) (aOR = 3.55, 95% CI: 0.48-26.46) definitions; however, a significant association was observed for the US CDC case definition (aOR = 3.56, 95% CI: 1.21-10.45). Other significant case definitions included having at least one systemic symptom (aOR = 4.54, 95% CI: 1.74-11.82) and fever with one additional systemic symptom (aOR = 9.89, 95% CI: 2.28-42.84).

DISCUSSION

Findings of this study are consistent with the results published by Menni et al, which also demonstrated a strong association between COVID-19 diagnosis and systemic symptoms; however, our findings provide additional insight to inform outbreak management practices and policies in LTC facilities. Our study also contributes to the growing evidence for mild/atypical presentations of COVID-19 particularly among the elderly, such as dizziness, nausea, and vomiting are not reported in 1B due to extremely broad confidence intervals. (C and D) Depict aORs (on a log10 scale) for seropositivity of symptom clusters (Appendix A) among the entire population (1C) or among individuals with a negative or no NAAT test prior to serological testing (1D). Anosmia, dizziness, nausea, and vomiting are not reported in 1B due to extremely broad confidence intervals. (C and D) Depict aORs (on a log10 scale) for seropositivity of symptom clusters (Appendix A) among the entire population (1C) or among individuals with a negative or no NAAT test prior to serological testing (1D). Anosmia, loss of smell/taste; SOB, shortness of breath/difficulty breathing; PHAC, Public Health Agency of Canada; US CDC, United States Centre for Disease Control; European CDC, European Centre for Disease Prevention and Control; WHO, World Health Organization.
generalized to other settings with caution, as the study was conducted in an outbreak setting with a high pretest probability for COVID-19.

The use of serological testing introduced some additional limitations. Baseline serological testing was not available at the start of the outbreaks and thus prior cases may not have been identified; however, both LTCF facilities represent the earliest COVID-19 outbreaks and cases in Canada, reducing the theoretical probability of prior infection to the start of the outbreak. Due to the rapid and evolving nature of the pandemic response, there is also potential risk for misclassification bias, as the clinical and diagnostic laboratory data structures used to compare and interpret serology results underwent continual quality improvement and reconciliation. While diagnostic misclassification may also occur due to the performance characteristics of COVID-19 serological assays, tests used in this evaluation were found by the performing laboratory to have specificity of 97%-99.5% and sensitivity of up to 98% at >14 days from symptoms onset. An orthogonal approach to the interpretation of test results further improved the overall specificity.

**CONCLUSION**

Our serological survey demonstrates that generalized/nonspecific symptoms and repetitive negative NAAT testing are highly associated with seropositivity. The findings of this survey can help inform case identification when managing COVID-19 outbreaks in LTCFs.

**CONTRIBUTION STATEMENT**

All authors made substantial contributions to the manuscript, including the conception/design (RV, AH, IS, MMu, PL), data acquisition (IS, MMu, MMc, PL, MK, AM, NC, SB, MS), data analysis (RV, CG), and interpretation of data for the work (all authors). RV initially drafted the manuscript, with all authors revising it critically for important intellectual content. All authors provide final approval of the version to be published and agreed to be accountable for all aspects of the work.

**SUPPLEMENTARY MATERIALS**

Supplementary material associated with this article can be found in the online version at https://doi.org/10.1016/j.ajic.2020.10.009.

**References**

1. Hsu AT, Lane N. Impact of COVID-19 on residents of Canada’s long-term care homes – ongoing challenges and policy response. Int Long Term Care Policy Netw. 2020. Available at: https://ltccovid.org/wp-content/uploads/2020/04/LTC-COVID19-situation-in-Canada-22-April-2020-1.pdf. Accessed October 23, 2020.

2. Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis. 2020;20:758–759.

3. Jartti L, Langen H, Söderlund-Venermo M, Vuorinen T, Ruuskanen O, Jartti T. New respiratory viruses and the elderly. Open Respir Med J. 2011;5:61–69.

4. Van Caeseele P, Bailey D, Forgie SE, Dingle TC, Krajden M. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. CMAJ. 2020;192:E572–E579.

5. Roche. cobas® SARS-CoV-2 Test. Available at: https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-test.html. Accessed October 22, 2020.

6. Mensi C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26:1037–1040.

7. Vetter P, Yu DL, L’Huillier AG, Schübler M, Kaiser L, Jacquerioz F. Clinical features of COVID-19. BMJ. 2020;369:m1470.

8. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility – King County, Washington, March 2020. Morb Mortal Wkly Rep. 2020;69:377–381.

9. Yong SEF, Anderson DE, Wei WE, et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect Dis. 2020;20:809–815.

10. Skowronski DM, Sekirov I, Sabaduc S, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-surveys before and after first wave measures in British Columbia, Canada, March-May 2020. medRxiv. 2020.

11. Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect. 2020;9:833–836.

12. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–848.